{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:14:22Z","timestamp":1784826862235,"version":"3.55.0"},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A 52-year-old, first-time blood donor presented with panreactivity during routine antibody screening. Current serologic evaluation showed uniform 2+ reactivity by the gel-indirect antiglobulin test and the conventional tube low-ionic-strength saline\u2013indirect antiglobulin test. The molecular analyses revealed a homozygous 17\u2013base pair deletion spanning nucleotides 64\u201380 in exon 3 of\n                    <jats:italic>SMIM1<\/jats:italic>\n                    (\n                    <jats:italic>VEL*01N.01\/VEL*01N.01<\/jats:italic>\n                    ), confirming the Vel-null phenotype. The antibody was identified as anti-Vel IgG3, reacting in tube testing, exclusively in the anti-human globulin phase. We present the first case of a Vel-null alloimmunized donor identified in Uruguay and describe the serologic, molecular, and functional characteristics of the associated antibody.\n                  <\/jats:p>","DOI":"10.2478\/immunohematology-2026-009","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:58:39Z","timestamp":1784825919000},"page":"48-51","source":"Crossref","is-referenced-by-count":0,"title":["First Vel-null alloimmunized blood donor identified in Uruguay"],"prefix":"10.2478","volume":"42","author":[{"given":"Martin","family":"Tucuna","sequence":"first","affiliation":[{"name":"1 Servicio Nacional de Sangre , Montevideo , Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Antonieta","family":"Nu\u00f1ez","sequence":"additional","affiliation":[{"name":"2 Clinica Santa Mar\u00eda , Santiago , Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pontigo","sequence":"additional","affiliation":[{"name":"2 Clinica Santa Mar\u00eda , Santiago , Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Cardoso","sequence":"additional","affiliation":[{"name":"3 Funda\u00e7\u00e3o Pr\u00f3-Sangue , S\u00e3o Paulo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taynara","family":"Vieira","sequence":"additional","affiliation":[{"name":"3 Funda\u00e7\u00e3o Pr\u00f3-Sangue , S\u00e3o Paulo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gularte","sequence":"additional","affiliation":[{"name":"1 Servicio Nacional de Sangre , Montevideo , Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Guigou","sequence":"additional","affiliation":[{"name":"1 Servicio Nacional de Sangre , Montevideo , Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittina","family":"Gruosso","sequence":"additional","affiliation":[{"name":"1 Servicio Nacional de Sangre , Montevideo , Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Lopez","sequence":"additional","affiliation":[{"name":"1 Servicio Nacional de Sangre , Montevideo , Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072316583393960_j_immunohematology-2026-009_ref_001","doi-asserted-by":"crossref","unstructured":"Storry JR, J\u00f6ud M, Christophersen MK, et al. Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype. Nat Genet 2013;45:537\u201341.","DOI":"10.1038\/ng.2600"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_002","doi-asserted-by":"crossref","unstructured":"Cvejic A, Haer-Wigman L, Stephens JC, et al. SMIM1 underlies the Vel blood group and influences red blood cell traits. Nat Genet 2013;45:542\u20135.","DOI":"10.1038\/ng.2603"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_003","doi-asserted-by":"crossref","unstructured":"Storry JR, Castilho L, Chen, Q, et al. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Terminology: report of the Seoul and London meetings. ISBT Science Series 2016;11:118\u201322.","DOI":"10.1111\/voxs.12280"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_004","doi-asserted-by":"crossref","unstructured":"Reid ME, Lomas-Francis C, Olsson M. The blood group antigen factsbook. 3rd ed. London, UK: Academic Press, 2012:667\u20138.","DOI":"10.1016\/B978-0-12-415849-8.00041-7"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_005","doi-asserted-by":"crossref","unstructured":"Daniels G. Human blood groups. 3rd ed. Oxford, UK: Wiley-Blackwell, 2013.","DOI":"10.1002\/9781118493595"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_006","doi-asserted-by":"crossref","unstructured":"Cardoso R, Vieira T, Conrado M, et al. Determination of IgG1 and IgG3 subclasses of red blood cell antibodies: an important tool for predicting harmfulness. Vox Sang 2026;121:625\u201331.","DOI":"10.1111\/vox.70201"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_007","unstructured":"Nance SJT. The monocyte monolayer assay, an in vitro method for prediction of in vivo survival of transfused incompatible red blood cells: a review. Immunohematology 2023;39:61\u20139."},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_008","doi-asserted-by":"crossref","unstructured":"Garratty G. Arndt P. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004;44:1273\u201381.","DOI":"10.1111\/j.1537-2995.2004.03427.x"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_009","doi-asserted-by":"crossref","unstructured":"Ballif B, Helias V, Peyrard T, et al. Disruption of SMIM1 causes the Vel\u2013 blood type. EMBO Mol Med 2013;5:751\u201361.","DOI":"10.1002\/emmm.201302466"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_010","doi-asserted-by":"crossref","unstructured":"Siegel D, Sch\u00f6rner E.J, Sch\u00f6rner, et al. Molecular identification of Vel-negative blood donors in a population from southern Brazil. Vox Sang 2026;121:384\u20139.","DOI":"10.1111\/vox.70187"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_011","doi-asserted-by":"crossref","unstructured":"Cedergreen B, Giles C, Ikin E. The Vel blood group in northern Sweden. Vox Sang 1976;31:344\u201355.","DOI":"10.1111\/j.1423-0410.1976.tb04658.x"},{"key":"2026072316583393960_j_immunohematology-2026-009_ref_012","doi-asserted-by":"crossref","unstructured":"Peyrard T, Pham BN, Le Pennec PY, et al. The rare blood groups: a public health challenge. Transfus Clin Biol 2008;15:109\u201319.","DOI":"10.1016\/j.tracli.2008.02.001"}],"container-title":["Immunohematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/immunohematology-2026-009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:58:41Z","timestamp":1784825921000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/immunohematology-2026-009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.2478\/immunohematology-2026-009"],"URL":"https:\/\/doi.org\/10.2478\/immunohematology-2026-009","relation":{},"ISSN":["1930-3955"],"issn-type":[{"value":"1930-3955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}